TY  - JOUR
AU  - Oubari, Sara
AU  - Papathanasiou, Maria
AU  - Michel, Lars
AU  - Rassaf, Tienush
AU  - Thimm, Andreas
AU  - Hagenacker, Tim
AU  - Ehling, Daniela
AU  - Wieczorek, Stefan
AU  - Naser, Eyad
AU  - Hegenbart, Ute
AU  - Schönland, Stefan
AU  - Dührsen, Ulrich
AU  - Reinhardt, Hans Christian
AU  - Carpinteiro, Alexander
TI  - Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival.
JO  - Annals of hematology
VL  - 104
IS  - 3
SN  - 0939-5555
CY  - New York
PB  - Springer
M1  - DKFZ-2025-00604
SP  - 1777-1788
PY  - 2025
N1  - 2025 Mar;104(3):1777-1788
AB  - Systemic light-chain amyloidosis (AL) is an acquired protein misfolding disease characterized by deposition of immunoglobulin light-chain fibrils most often secreted from clonal plasma cells. In this retrospective study we analyzed the impact of iFISH aberrations on clinical characteristics and outcomes in 175 AL patients presented between 2015 and 2024. The most common aberrations were t(11;14) (57
KW  - +1q21 (Other)
KW  - AL amyloidosis (Other)
KW  - IFISH (Other)
KW  - Mayo stage (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40119178
DO  - DOI:10.1007/s00277-025-06256-7
UR  - https://inrepo02.dkfz.de/record/300104
ER  -